Oncotarget: Sacituzumab Govitecan In Triple-Negative Breast Cancer

Oncotarget: Sacituzumab Govitecan in Triple-Negative Breast Cancer

Sacituzumab Govitecan with Platinum Chemotherapy: Antitumor Effects | Oncotarget

Crosstalk Between Triple Negative Breast Cancer and Microenvironment | Oncotarget

Study of sacituzumab govitecan for triple-negative breast cancer

Dana-Farber Cancer Institute

Inhibition of Resistant Triple-negative Breast Cancer Cells | Oncotarget

Dr. Bardia on Sacituzumab Govitecan in Triple-Negative Breast Cancer

Real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer

ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC

ASCENT-04: sacituzumab govitecan and pembrolizumab in PD-L1-positive TNBC

Oncotarget: CRISPR Used in Triple Negative Breast Cancer Research

The ASCENT of sacituzumab govitecan in metastatic TNBC | Aditya Bardia

Medicine Matters oncology

Oncotarget | NOTCH1 Variants in Triple-Negative Breast Cancer

ASCENT: sacituzumab govitecan outperforms chemo in Black patients with TNBC

Final OS analysis of sacituzumab govitecan in TROPiCS-02

Efficacy of sacituzumab govitecan by Trop-2 expression in patients with mUC

ASCENT: sacituzumab govitecan shows promise in mTNBC patients

Dr Aditya Bardia Discusses the Advantages of Sacituzumab Govitecan for Triple-Negative Breast Cancer

Biomarker data point to wide use of sacituzumab govitecan in advanced TNBC | Sara Hurvitz

Medicine Matters oncology

ASCENT trial: sacituzumab govitecan for TNBC

Dr. Tagawa on Next Steps With Sacituzumab Govitecan in Advanced Urothelial Carcinoma